Targeting, Attacking, and Eradicating Cancers®
PEXA-VEC (JX-594) Clinical-stage oncolytic immunotherapy demonstrating both IT and IV delivery to tumors and induction of cancer specific antibodies
Direct Cell Lysis Tumor selective intratumoral replication of the virus leads to lysis of the infected cancer cell and spread to adjacent cancer cells
Adaptive Immune Response Induction of tumor-specific cytotoxic T-lymphocytes and “arming” for expression of therapeutic transgene products (e.g. GM-CSF) enhance immune response to the tumor
Vascular Shutdown Blood flow to tumors can be blocked following intratumoral replication and spread
